Search results for: Maria Lowe

OHE Innovation Policy Prize

…Deliver Pharmaceutical Innovation and The Lower Drug Costs Now Act and Pharmaceutical Innovation. We are delighted to launch a new £40,000 biennial prize fund. Our successes in driving this area forward are founded in our dedication…

2022 Innovation Policy Prize

…drug is sold at a higher price which increases revenue. But there is a marginal cost: lower demand for the drug as the price increases. It is well–known that the ability to…

Climate action is health action: OHE’s focus on sustainability

22 July 2025

…component of this, with the purpose of increasing uptake and incentivizing development of locally appropriate greenovations in lower-income countries.  We’ve also brought together experts across disciplines to identify the most…

Understanding the preferences of people with acute leukemia for different health outcomes

25 September 2025

…with pain/discomfort, anxiety/depression, and doing their usual activities. The percentages of people in the general population reporting problems on these dimensions were much lower in comparison, illustrating the impact of…

OHE’s submission to a parliamentary inquiry on UK drug shortages

6 October 2025

…direct investment into the UK was around 58% lower in 2023 (standing at £795 million) than in 2017 (when it was at £1.9 billion).   Concluding thoughts A general lesson from our…

Turning around the NHS: Reflections on the 2025 OHE Annual Lecture

14 October 2025

…treatable causes Professor Charlesworth also stated that public satisfaction with the NHS has fallen to its lowest level since records began in 1983. Access targets, as laid out in Lord Darzi’s…

Reflections from Adrian Towse on decades of HEOR research and impact

11 November 2025

…they want which involves understanding value and handling uncertainty appropriately. Second, whilst high income countries drive most innovation, we need to make sure it is available at lower prices to…

A global landscape analysis of access to tumour-agnostic therapies 

1 December 2025

…disparities in funding, infrastructure, and clinical integration, especially in lower-resourced settings. Emerging Policy Trends: Key developments include FDA and CDA-AMC guidance on TA-specific evidence generation and assessment, ESMO’s screening framework…

Novel devices: optimising drug delivery in multiple myeloma

9 December 2025

…the use of OBIs provides significant benefits by simplifying preparation and administration, reducing care burden and time requirements, and lowering the risk of physical strain and occupational injuries. These improvements…